Stefan Zwirner
Tuebingen, BW 72072, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Darizmetinib (HRX215): A Promising 1st-in-Class Liver Regenerating Drug in Phase 1b/2a Clinical Development, Targeting the Stress Signaling Protein Kinase MKK4.
Journal: Journal of medicinal chemistry
Published: May 06, 2026
Discovery of the First Highly Selective 1,4-dihydropyrido[3,4-b]pyrazin-3(2H)-one MKK4 Inhibitor.
Journal: Journal of medicinal chemistry
Published: July 11, 2025
A "Ligand First" Approach toward Selective, Covalent JNK2/3 Inhibitors.
Journal: Journal of medicinal chemistry
Published: May 22, 2025
First-in-class MKK4 inhibitors enhance liver regeneration and prevent liver failure.
Journal: Cell
Published: May 23, 2023
Experimental glioma with high bHLH expression harbor increased replicative stress and are sensitive toward ATR inhibition.
Journal: Neuro-oncology advances
Published: November 02, 2020
LXRα activation and Raf inhibition trigger lethal lipotoxicity in liver cancer.
Journal: Nature cancer
Published: June 25, 2020
Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours.
Journal: Nature communications
Published: November 26, 2018
Elimination of different leukaemia subtypes using novel CD89-specific human cytolytic fusion proteins.
Journal: British journal of haematology
Published: October 20, 2017
A Dual Role of Caspase-8 in Triggering and Sensing Proliferation-Associated DNA Damage, a Key Determinant of Liver Cancer Development.
Journal: Cancer cell
Published: January 23, 2016
Showing 1-9 of 9
Last Updated: 09/26/2026